What’s Trending?

Cannes Lions Health kicks off its sixth year Monday, and attendees are looking for some breakouts. As in breakthrough technology, barrier-breaking creativity, groundbreaking global ideas—and a chance to finally break with the backhanded compliment that Lions Health work is “good for pharma.” [...]
Fri, Jun 14, 2019
Source FiercePharma
Eighty employees of Wyoming's only drug manufacturing plant are feeling the pain of financially struggling Lannett. The opioid maker will close the plant in Cody and lay off its 80 remaining employees. [...]
Fri, Jun 14, 2019
Source FiercePharma
Sen. Bernie Sanders and Rep. Elijah Cummings looked into suspicious generic price fixing back in 2014. But they now know drugmakers responded to their probe with "polite f-u" letters, an email shows. They're asking the DoJ to prioritize its work on the subject. [...]
Fri, Jun 14, 2019
Source FiercePharma
The LGR will receive up to $67 million in funding over a five-year period. [...]
Fri, Jun 14, 2019
Source PharmaTimes
Over a third (36%) of respondents' staff have asked for faster digital technology systems. [...]
Fri, Jun 14, 2019
Source PharmaTimes
The couple behind China's Hansoh and Hengrui is among the biopharma industry's richest; Korean prosecutors grilled a top Samsung executive over accounting case; another Aurobindo plant is cited by the FDA; and more. [...]
Fri, Jun 14, 2019
Source FiercePharma
The drug demonstrated superiority to current standard-of-care to CellCept. [...]
Fri, Jun 14, 2019
Source PharmaTimes
The sourcebook covers six topics, which were identified as areas where further guidance would be of assistance. [...]
Fri, Jun 14, 2019
Source PharmaTimes
Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at [...]
Thu, Jun 13, 2019
Source WorldPharmaNews
Depression is a common and serious problem for older adults. Some 15 to 20 percent of people aged 65 and older who live independently deal with symptoms of major depressive disorder. For residents of nursing homes, the rates of depression may be as high as 50 percent. For some people, [...]
Wed, Jun 12, 2019
Source WorldPharmaNews
Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk.(1) The findings were reported today at the American Diabetes Association's 79th Scientific Sessions [...]
Tue, Jun 11, 2019
Source WorldPharmaNews
SMi Group
19 - 20 November 2019, London, UK. The global ophthalmic drug market size is expected to reach a value of $30 billion USD by 2023 with growing focus on alternative delivery approaches to replace intravitreal drug delivery and novel drug development being the key factors driving the market. [...]
Tue, Jun 11, 2019
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews